Rebecca Johnson, PhD

Amid mounting political and legal pressure, corporate DEI efforts, particularly in life sciences, are largely holding steady, with leadership, boards, and shareholders continuing to frame inclusion as a strategic driver of innovation, performance, and representative clinical research.

Although DEI remains a core tenet in pharma, strategies and goals have been reframed to align with the evolving political climate.

Advancing more inclusive and representative clinical trials through action and accountability.

Examining the implications of the recent US executive orders concerning diversity, equity, and inclusion pursuits—and the key questions each clinical trial stakeholder must now navigate.